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Abstract
Background: Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common disorder of
mitochondrial fatty acid β-oxidation and a target disease of newborn screening in many countries.
Case presentation: We report on two siblings with mild MCAD deficiency associated with a novel splice site
mutation in the ACADM gene. The younger sibling was detected by newborn screening, while the older sister was
missed, but diagnosed later on by genetic family testing. Both children were found to be compound heterozygous
for the common c.985A > G (p.K329E) mutation and a novel splice site mutation, c.600-18G > A, in the ACADM gene.
To determine the biological consequence of the c.600-18G > A mutation putative missplicing was investigated at
RNA level in granulocytes and monocytes of one of the patients. The splice site mutation was shown to lead to
partial missplicing of the ACADM pre-mRNA. Of three detected transcripts two result in truncated, non-functional
MCAD proteins as reflected by the reduced octanoyl-CoA oxidation rate in both patients. In one patient a decrease
of the octanoyl-CoA oxidation rate was found during a febrile infection indicating that missplicing may be
temperature-sensitive.
Conclusions: Our data indicate that the c.600-18G > A variant activates a cryptic splice site, which competes with
the natural splice site. Due to only partial missplicing sufficient functional MCAD protein remains to result in mild
MCADD that may be missed by newborn screening.
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Background
Medium-chain acyl-CoA dehydrogenase deficiency
(MCADD; MIM 201450) is an autosomal recessive
disorder of mitochondrial β-oxidation, caused by mu-
tations in the ACADM gene. The estimated prevalence
of MCADD from newborn screening ranges from 1 in
8,100 to 1 in 27,000 among populations of mostly
European descent and is less common in populations
of non-European origin [1]. Clinical manifestation com-
prises hypoketotic hypoglycemia, muscular hypotonia,
lethargy, vomiting, seizures, encephalopathy, coma, and
death. Since fatty acid oxidation is essential for energy
production during fasting and increased energy expend-
iture, metabolic decompensations are predominantly pre-
cipitated by metabolic stress. In the absence of screening,
mortality is up to 26 % [2] and many surviving patients
develop severe neurocognitive impairment [1–5]. Since
the implementation of tandem mass spectrometry-based
newborn screening (NBS) the prognosis of this inherited
metabolic disease has significantly improved [6–8]. How-
ever, NBS also identifies mild and potentially asymptom-
atic cases and sometimes also heterozygous individuals,
who are at no risk of clinical symptoms.
The typical MCADD acylcarnitine pattern includes
elevated levels of C6, C8, C10 and C10:1 acylcarnitines as
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well as increased disease-specific acylcarnitine ratios [C8]/
[C10], [C8]/[C12] and [C8]/[C2] [9]. Additionally, elevated
levels of hexanoylglycine, isohexanoylglycine, suberylgly-
cine, and phenylpropionylglycine may be found in the
urine of affected individuals. Enzyme activity of MCAD
can be determined by measurement of octanoyl-CoA or
phenylpropionyl-CoA oxidation rate in lymphocytes and
may be used for risk assessment [10]. This is of special
importance as the molecular diagnostic after a suggestive
NBS result often leads to the identification of novel DNA
variants, or “variants of unknown significance” [11].
We report on two asymptomatic siblings with a
biochemically mild MCADD phenotype (low levels of
MCAD-typical metabolites and high residual enzyme
activity). Only one of them was detected by NBS,
while the other one was missed. Mutation analysis
revealed a known pathogenic missense mutation in
combination with a novel splice site mutation in the
ACADM gene. The consequences of this splice site
mutation were further characterized.
Patients
Consent
All individuals in our study were recruited by physician-
initiated referral. The study was conducted in accord-
ance with the Declaration of Helsinki protocols and
approved by the institutional ethics review board of
Freiburg University Hospital, Germany. Written informed
consent for molecular studies was obtained from the
affected individuals and/or their legal guardians in ac-
cordance with current German law (GenDG). A copy of
the written consent is available for review by the Editor of
this journal. Control samples and primary cells were
collected from ancestry-, sex- and age-matched healthy
individuals under the same criteria and regulations.
Case presentations
Patient 1, a 7-year-old girl, is the first child of non-
consanguineous German parents. She was born spon-
taneously at 41 weeks of gestation after an uneventful
pregnancy. Birth weight, birth length and head circum-
ference were 3280 g (56th percentile), 53 cm (87th
percentile) and 35 cm (50th percentile), respectively.
Three hours after birth she was admitted to the inten-
sive care unit with suspected newborn infection. She
was pale, tachypnoeic and required CPAP ventilation
with up to 60 % oxygen. Laboratory parameters were
indicative of systemic infection (Interleukin 6 727 pg/
ml, reference range < 30 pg/ml) and chest X-ray re-
vealed pneumonic infiltrations. Under antibiotic treat-
ment her general condition ameliorated quickly, and
the child was dismissed from hospital on day 10. NBS
results including acylcarnitine analysis were unremark-
able. After dismission from hospital no further prob-
lems occurred and the child developed normally.
Five years later her younger sister, patient 2, was born
and NBS was suggestive of MCADD. Urinary organic
acid analysis biochemically confirmed the diagnosis.
Mutation analysis revealed compound heterozygosity
for the common missense mutation c.985A > G and an
intronic sequence variant, c.600-18G > A, which has not
been described previously. Genetic family screening was
performed showing that the older sister (patient 1) was
also compound heterozygous for the same two mutations.
Heterozygosity for the c.985A >G (p.K329E) mutation
was detected in the healthy mother, while the healthy
father and the healthy 3-year-old brother were found to
be heterozygous for the intronic sequence variant. An
overview on the ACADM genotypes of the two patients,
their brother and their parents is shown in Fig. 1.
In the following 3 years acylcarnitine analyses in dried
blood spots of both girls were performed repeatedly at
Fig. 1 Pedigree of the patient’s family showing haplotypes for the ACADM allele variants in the patient, her siblings and her parents. Males are
presented by squares, females by circles. Allele variants without mutation are represented by an open square or circle. Mutated allele variants are
indicated by a solid (c.600-18G > A) or a shaded (c.985A > G) square or circle, respectively
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times of physical well-being and yielded variable results
(Table 1): In patient 1 three of four samples showed an
unremarkable acylcarnitine pattern while patient 2 usu-
ally displayed a “typical” MCAD pattern. Free carnitine
concentrations were always within the normal range.
Analysis of organic acids in urine showed only mildly
elevated concentrations of hexanoylglycine and isohex-
anoylglycine in both patients (Table 1). Suberylglycine
was only detected in few samples and the concentration
of dicarboxylic acids was usually not elevated. The
oxidation rate of octanoyl-CoA was measured in lym-
phocytes of both patients. In patient 1 enzyme testing
was performed during a febrile episode yielding 17 % of
healthy controls. In patient 2, octanoyl-CoA oxidation
rate was determined twice, at time of physical well-
being and during fever showing a residual activity of
24 % and 13 %, respectively (Table 1).
No inborn errors of metabolism had been detected in
other family members so far, and no cases of unex-
plained death in infancy were reported. When specific-
ally asked, the parents reported that the older sister
(patient 1) had well tolerated overnight-fasts of 9–10 h
at the age of 9 months. She had had several minor
febrile infections including gastroenteritis within her
first year of life. At the age of 4.5 years she had suf-
fered from a severe febrile gastroenteritis. During this
episode she ate and drank only sparingly for about 4
to 5 days. Despite this catabolic state her vigilance had
always been normal with no signs of somnolence or
lethargy and clinical symptoms of hypoglycemia were
not observed.
Materials and methods
Oxidation rate of medium-chain acyl-CoAs
Determination of the MCAD residual activity was achieved
by assaying the oxidation of octanoyl-CoA and C10-CoA in
lymphocytes by HPLC as described previously [10].
Mutation analysis
Genomic DNA was extracted from EDTA blood with
QIAmp® DNA Mini Kit (Qiagen, Hilden, Germany). All
exons and parts of the flanking intronic regions of the
ACADM gene were amplified according to standard proto-
cols using Quick-Load® Taq 2X Master Mix (New England
Biolabs, Frankfurt, Germany). Sequencing reactions were
performed with the BigDye® Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems, Weiterstadt, Germany)
(primer sequences are available on request) and were
analysed using a 3730xl DNA Analyzer (Applied Biosys-
tems, USA). Electropherograms were evaluated with the
Sequencing Analysis Software v5.4 (Applied Biosystems,
USA). To predict a putative missplicing effect of the se-
quence variant c.600-18G >A the Alamut software 2.3.2
was used.
Definition of RNA splicing patterns
Peripheral blood samples were fractionated into mono-
nuclear cells and granulocytes using the standard Ficoll
protocol. Total RNA was isolated from these cells using
TRIzol® Reagent (Life Technologies, USA) followed by a
phenol-chloroform extraction, treatment with DNAse I
(Roche, Mannheim, Germany) and purification with the
RNeasy Mini Kit (Quiagen, Hilden, Germany). Reverse
Table 1 Biochemical data of two siblings with mild MCAD deficiency
Patient 1 Patient 2 Controls
Newborn screening Unremarkable Suggestive of MCADD Unremarkable
Confirmatory testing
Acylcarnitines in dried blood spots (at different time points) C6 0.06–0.27 μmol/l 0.13–0.38 μmol/l <1 μmol/l
C8 0.11–1.56 μmol/l 0.31–1.5 μmol/l <0.4 μmol/l
C10 (including C4:1-DC) 0.07–0.74 μmol/l 0.16–0.93 μmol/l <0.2 μmol/l
C10:1 0.07–0.63 μmol/l 0.13–0.7 μmol/l <0.2 μmol/l
[C8]/[C10] 1.2–2.46 1.62–2.86 <5
[C8]/[C12] 4.97–19.3 6.46–17.1 <5
[C8]/[C2] 0.01–0.09 0.02–0.4 <0.02
Urinary organic acids (at different time points) Hexanoylglycine +/ n.d. +/ n.d. n.d.
Isohexanoylglycine +/ n.d. +/ n.d. n.d.
Suberylglycine +/ n.d. +/ n.d. n.d.
Dicarboxylic acids Not elevated Not elevated
Enzyme activity measurements in lymphocytes Octanoyl-CoA-oxidation 17 % (during fever) 24 % (without fever) 100 %
13 % (during fever)
n.d. not detectable, + detectable in traces
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transcription of RNA into cDNA with oligo-dT primers
and M-MLV RT (Life Technologies, USA) was con-
ducted according to the manufacturer’s protocol. The
subsequent PCR amplification was performed with
specific primers spanning from exons 7 to 9 of the
ACADM gene (For_AACCTGGAGCAGGCTCTGAT
and Rev_ACCAGCTCCGTCACCAATTA). PCR prod-
ucts were detected by electrophoresis on a 2 % agar-
ose gel. After excision and gel extraction with the
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany),
PCR products were evaluated by sequencing analysis
(3130xl Genetic Analyzer, Applied Biosystems, USA).
Comparative alignments with the reference coding se-
quence were carried out by the DNA Sequence Analysis
Software Sequencher 4.9 (Gene Codes Corporation,
USA).
PCR products of the patient’s monocytes cDNA were
ligated into the pCR™II Vector and transformed into
TOP10F’ Chemically Competent E. coli with the TA
Cloning® Kit (Life Technologies, USA), according to the
manufacturer’s protocol. Plasmids containing the differ-
ent PCR products were purified with the FastPlasmid
Mini Kit (5 Prime, Hamburg, Germany). After an EcoRI
digestion (New England Biolabs, Frankfurt, Germany)
fragments were detected on an agarose gel and different
splice variants were identified by their predicted size.
To confirm the proportion of the different splicing
variants gel fragments were excised, extracted and
sequenced as described above.
Fluorescent fragments of DNA were generated via
PCR amplification of the cDNA gained from granulo-
cytes and monocytes of the patient and two independent
controls with the For_AACCTGGAGCAGGCTCTGAT
primer and a Rev_ACCAGCTCCGTCACCAATTA 5′
FAM labelled primer, respectively. Fragments were
separated using capillary electrophoresis (3130xl Gen-
etic Analyzer, Applied Biosystems, USA) and sized by
comparison to a size standard (GeneScan™ 500 LIZ®
Size Standard, Life Technologies, USA).
Results
In the Single Nucleotide Polymorphism database (dbSNP)
the sequence variant c.600-18G > A is annotated as an
intronic variant with unknown clinical relevance. In
silico splice prediction with the Alamut Interactive
Biosoftware was performed and all tools integrated in
this application (Splice Site Finder (SSF), MaxEntScan
(MES), Neural Network (NNSplice) and GeneSplicer)
identified the variant as a possible candidate for spli-
cing alteration (Additional file 1: Table S1).
To determine the biological consequence of the
c.600-18G > A mutation putative missplicing was in-
vestigated at RNA level in granulocytes and monocytes
of patient 1. Besides the expected PCR products of ca.
323 bp, we observed additional PCR products of 215
and 294 bp which were only present in the patient’s
sample (Fig. 2). Gel extraction followed by sequencing
revealed either a total (215 bp) or partial deletion
(294 bp) of exon 8.
In silico translation of both splice variants with the
help of the ExPASy translate tool predicts premature
stop in the patient’s variants due to missplicing and
therefore truncated proteins leading most likely to
dysfunctional enzyme (Fig. 3).
To quantify missplicing two different approaches
were used. In the first approach, cDNA of the patient’s
monocytes was cloned into the pCRII-TOPO vector.
With this method, the different RNA splicing variants
could be identified by their calculated transcript
lengths. The different splice variants were further
confirmed by sequencing. The evaluation of 28 tran-
scripts revealed missplicing in half of all PCR products:
Besides the 14 wild type sequences, 5 sequences (18 %)
showed skipping of exon 8, and in 9 sequences (32 %)
partial deletion of exon 8 could be confirmed (Additional
file 2: Figure S1). Consistent with this finding, the second
quantitation approach, based on a fragment analysis with
a 5′ reverse FAM labelled primer, revealed an approxi-
mate ratio of 45:55 of aberrant splicing versus normal
Fig. 2 A novel mutation in the ACADM gene results in aberrant splicing. Gel documentation visualizes the PCR product of a region of 323 bp
from exon 7 to 9 of the ACADM gene in cDNA of control granulocytes (CTL GRAN) as well as of monocytes (MNC) and granulocytes (GRAN) of
patient 1. Arrows point to the additional PCR products that were detected using cDNA of the patient’s granulocytes and monocytes. Analysis of
the two additional PCR products in the gel eluates of the patient’s samples revealed missplicing resulting in either a partial loss of exon 8
(fragment of 294 bp, upper arrowhead) or complete skipping of exon 8 (fragment of 215 bp, lower arrowhead)
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splicing in the patient’s monocytes and an approximate
ratio of 60:40 in the patient’s granulocytes, respectively
(Fig. 4, Additional file 3: Table S2). Interestingly, a minor
amount (~10 %) of the transcript with exon 8 skipping could
also be detected in the control sample. Therefore, it is con-
ceivable that ‘natural’ missplicing of the ACADM RNA also
occurs in healthy individuals although to a very limited
extent as we could not detect this transcript in the gel.
In a last step, the transcript sequences were scanned
for possible cryptic splice sites and a scheme for the
aberrant splicing process could be developed. In our
model, the c.600-18G > A mutation in intron 7 leads to a
splice pattern with strong cryptic donor and acceptor
sites that compete with the natural splice sites, resulting
either in partial deletion or complete skipping of exon 8
(Fig. 5). We, therefore, presume the sequence variant
c.600-18G > A to be likely pathogenic which is also
reflected by the reduced octanoyl-CoA oxidation rate in
both patients.
Discussion
We here report on two siblings with mild MCADD, of
whom only one was identified by newborn screening. The
genotypes of patients identified after implementation of
NBS differ from those identified in patients with clinical
manifestation [12, 13]. The mutation c.985A >G is the
Fig. 3 Missplicing leads to premature stop codons and therefore truncated MCAD protein products. Shown are extracts of chromatograms
representative for the different splice variants. Specific regions are indicated (exon 7 to exon 9). In silico protein products of the ACADM gene
were generated, the amino acid sequence is displayed under the chromatogram extracts. Both forms of missplicing lead to premature stop
codons and therefore truncated protein products which only differ in two amino acids (WN) at the C-terminus of the truncated protein (a and b
corresponding to fragments 294 bp and 215 bp, respectively). c The region highlighted in grey in the chromatogram reflects the region that
is partly deleted in the patient’s cDNA shown in A due to missplicing. Probable cryptic donor and acceptor sites that lead to missplicing
are indicated. (CTL GRAN = control granulocytes, MNC =monocytes GRAN = granulocytes)
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most common mutation in clinically detected patients
and has been found in 80 % of these individuals in
homozygosity and in 18 % in heterozygosity [14, 15].
This mutation is considerably less frequent in individuals
diagnosed by NBS, while numerous novel mutations
including a second prevalent mutation, c.199 T > C, have
been identified in this group of patients [12, 13]. Indi-
viduals carrying these mutations often show signifi-
cantly lower concentrations of disease-characteristic
acylcarnitines [13, 14]. Our patients were found to be
compound heterozygous for the common c.985A > G
mutation and a novel splice site mutation, c.600-18G >A.
The c.985A >G mutation (K329E) is well characterized
with respect to its functional consequences. The MCAD
protein is a tetramer of 4 identical subunits. The amino
acid change K329E is located in the C terminal α domain
of the enzyme and compromises tetramer assembly by
affecting helix-helix interactions resulting in degradation
of the mutant enzyme [16]. The K329E protein variant
has been shown to be thermosensitive [17]. Therefore,
Fig. 4 Percental amounts of different splice products (studied in patient 1). Previously identified splicing fragments were confirmed with
fragment analysis (H = height, S = size of the fragment). Data of the fragment analysis were tabularized (Additional file 3: Table S2) and single
fragment heights were set in relation to overall heights (summarized fragment heights of the particular sample) to determine the percental
distribution of the different splice products in each sample. (CTL GRAN = control granulocytes, MNC =monocytes, GRAN = granulocytes)
Fig. 5 Working model of the splice reaction with cryptic donor and acceptor sites. Exons are boxed, introns are represented by lines. The
mutation in intron 7 of the patient leads to the activation of cryptic donor and acceptor sites that compete with the natural splice site thereby
resulting in partial deletion (variant 1) or skipping of exon 8 (variant 2)
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febrile episodes may additionally affect protein stability
and function in patients carrying this mutation and
may aggravate energy deficiency [18].
The c.600-18G > A mutation has not been described
previously. Variant analysis using a prediction software
indicated a splice altering mutation. Indeed, we could
demonstrate the pathogenicity of this mutation by proof
of aberrant splicing. We propose an activation of cryptic
splice sites that leads to weakening of the natural splice
sites and generates shortened transcripts. Although
missplicing is not complete, the combination of both
mutations in the compound heterozygous state may ac-
count for the reduced enzyme activity and biochemical
abnormalities in our patients. The residual enzyme activity
measured with octanoyl-CoA as substrate was 13-24 % of
healthy controls. These values are higher than those
usually found in patients with “classical” MCADD, but
lower than those found in heterozygous carriers [19]
indicating that the splice site mutation really has a
compromising effect on the MCAD protein. Missplicing is
known to be highly tissue and cell type specific as can be
seen from the different splicing patterns in granulocytes
and monocytes of our patients. Though no prediction
of the prevalence of missplicing in hepatocytes can be
made from our data, it is conceivable that there is a
shift in favour of the aberrant splice product in this cell
type. Furthermore, it has been reported that splicing
processes can be temperature-sensitive. In case that
the original splice site is still functional temperature
may affect splice site selection in favour of the aberrant
splice site [20, 21]. Interestingly, we found a lower re-
sidual activity during a febrile infection than at time of
physical well-being in patient 2 (Table 1). In the con-
text of MCADD, in which metabolic decompensations
are often triggered by febrile infections, this may be of
clinical relevance. Enhanced missplicing during epi-
sodes of increased energy expenditure may aggravate
the cellular energy deficiency and therefore have clin-
ical consequences.
Only one of the two sisters was identified by newborn
screening due to a characteristic acylcarnitine pattern.
This is notable as it has been shown that even carriers of a
single c.985A >G mutation may display mildly elevated
C8 acylcarnitine concentrations [22, 23]. Lehotay et al.
reported significantly higher C8 concentrations of 0.302
± 0.09 μmol/l in c.985A > G heterozygotes compared to
healthy controls, while the C8 concentration in our com-
pound heterozygous patient (0.17 μmol/l) was even
below this range. High C8 levels have been shown to be
associated with severe mutations including the common
c.985G > C mutation (in homozygosity), deletions, non-
sense or splice site mutations [24]. In a study with 34
MCAD deficient individuals evaluating the correlation
between genotype and biochemical phenotype, patients
homozygous for c.985A > G had the highest levels of
neonatal octanoylcarnitine followed by compound het-
erozygotes of c.985A > G and other mutations. Patients
without c.985A > G and compound heterozygotes for
c.985A > G and c.199 T > C had the lowest levels of C8.
According to this, an intermediate elevation of the C8
acylcarnitine concentration would have been expected
in our patient.
Even if the high residual MCAD activity and the
mild biochemical expression in our patients are sug-
gestive of a presumably low clinical penetrance, the
potential risk of metabolic decompensation during se-
vere catabolism cannot be estimated and the clinical
relevance of mild MCADD is difficult to establish. Al-
though the majority of symptomatic patients present
within the first three years of life, several late onset
cases have been reported [25, 26]. Both girls have
remained asymptomatic so far, however, they are only
3 and 7 years old, respectively. Nevertheless, it is of
great interest that patient 1 has experienced many
infections and catabolic conditions before diagnosis by
family screening not resulting in any clinical symp-
toms. The natural course of the disease in individuals
with novel mutations is generally unknown [16]. Many
of these children may remain asymptomatic even
without detection by NBS. This is reflected by the
much higher detection rate of MCADD by NBS
compared to clinically detected cases in unscreened
populations. In contrast, one more recent study on
structural alterations of several mutant variants pro-
posed that novel mutations found in NBS, including
the c.199 T > C mutation, do not bear a lower risk of
metabolic decompensation than that associated with
mutations detected in clinically ascertained patients
[16], although, to our knowledge, only one individual
carrying the c.199 T > C mutation together with a sec-
ond mutation has ever been symptomatic during
follow-up. The mother sought emergency room care
for the infant two times in the first year for listlessness
associated with gastroenteritis. At age 22 months al-
tered mental status and variable hypo- and hypergly-
cemia were reported during hospital admission for
hand/foot/mouth disease [24]. Residual enzyme activ-
ities in patients with proposed mild MCADD are in
some cases in the same activity range as in definite
heterozygous parents questioning the clinical rele-
vance of the mutations [10]. So far, there is no consen-
sus to consider certain ACADM genotypes as safe and
protective from clinical symptoms [16, 24], however,
we are also aware of an overtreatment of many indi-
viduals identified by newborn screening. The same un-
certainty is true with respect to the interpretation of
the biochemical phenotype despite a strong relation-
ship between initial C8 levels and outcome [24].
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Conclusion
The novel splice variant c.600-18G > A was shown to
activate a cryptic splice site, which competes with the
natural splice site. Due to only partial missplicing
sufficient functional MCAD protein remains to result
in clinically and biochemically mild MCADD that
may be missed by newborn screening. If patients with
such mild phenotypes are at risk of fatal metabolic
decompensations remains a matter of debate.
Additional files
Additional file 1: Table S1. In silico splice prediction of the Alamut
Interactive Biosoftware. Note that all tools integrated in this application
(Splice Site Finder (SSF), MaxEntScan (MES), Neural Network (NNSplice)
and GeneSplicer) identified the variant as a possible candidate for
splicing alteration.
Additional file 2: Figure S1. Gel documentation of PCR products of
the patient’s monocyte cDNA after EcoRI digestion. Fragments were
detected on an agarose gel. Splice variants were identified by their
predicted size and confirmed by sequence analysis. Missplicing was
detected in half of the fragments.
Additional file 3: Table S2. Tabularized data of the fragment analysis.
Different fragments are indicated with I (215 bp), II (294 bp) or III
(323 bp). Single fragment heights were set in relation to overall heights
(summarized fragment heights of the particular sample) to determine the
percental distribution of the different splice products in each sample. CTL
GRAN = control garanulocytes, Patient GRAN = granulocytes of patient,
Patient MNC =monocytes of patients.
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